SAN DIEGO—(BUSINESS WIRE)—April 24, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatthe United States Adopted Names (USAN) Council has approved thenonproprietary name "pimavanserin tartrate" for ACADIA's drugcandidate ACP-103.
The USAN Council serves health professionals in the United Statesby selecting simple, informative, and unique nonproprietary names fordrugs by establishing logical nomenclature classifications based onpharmacological and/or chemical relationships to ensure that druginformation is communicated accurately and unambiguously. The USANCouncil aims for global standardization and unification of drugnomenclature by working closely with the International NonproprietaryName Programme of the World Health Organization and various nationalnomenclature groups.
About Pimavanserin
Pimavanserin tartrate (previously referred to as ACP-103) is anovel, potent and selective 5-HT2A inverse agonist that ACADIAdiscovered and is developing as a co-therapy for schizophrenia and asa treatment for Parkinson's disease psychosis and sleep maintenanceinsomnia. In March 2007, ACADIA announced positive top-line resultsfrom its Phase II schizophrenia co-therapy trial, which demonstrated anumber of important advantages of co-therapy combining pimavanserinand low-dose risperidone compared to a standard dose of risperidone,including enhanced efficacy, a faster onset of antipsychotic action,and an improved side-effect profile. In addition, ACADIA is preparingto initiate the first of two planned pivotal trials in its Phase IIIprogram with pimavanserin for the treatment of Parkinson's diseasepsychosis during the first half of 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at large unmet medical needs, includingschizophrenia, Parkinson's disease psychosis, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historicalin nature are forward-looking statements. These statements include butare not limited to statements related to benefits to be derived fromACADIA's drug development programs, including the potential advantagesof the use of pimavanserin as a co-therapy for schizophrenia and as atreatment for Parkinson's disease psychosis and sleep maintenanceinsomnia. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially fromthose projected in any of such statements due to various factors,including the risks and uncertainties inherent in clinical trials anddrug development and commercialization, including the uncertainty ofwhether results in testing of pimavanserin to date will be predictiveof results in later stages of development. For a discussion of theseand other factors, please refer to ACADIA's annual report on Form 10-Kfor the year ended December 31, 2006 as well as other subsequentfilings with the Securities and Exchange Commission. You are cautionednot to place undue reliance on these forward-looking statements, whichspeak only as of the date hereof. This caution is made under the safeharbor provisions of the Private Securities Litigation Reform Act of1995. All forward-looking statements are qualified in their entiretyby this cautionary statement and ACADIA undertakes no obligation torevise or update this press release to reflect events or circumstancesafter the date hereof.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.